Drug Profile
Research programme: anti-cancer therapeutics - Mundipharma EDO
Alternative Names: EDO 772P/B776; EDO B278; EDO-B776Latest Information Update: 27 Aug 2020
Price :
$50
*
At a glance
- Originator Mundipharma EDO
- Class Antineoplastics; Immunoconjugates
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 26 Aug 2020 Discontinued - Preclinical for Solid tumours in Switzerland (Parenteral) before August 2020 (Mundipharma research's pipeline - August 2020)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Solid-tumours in Switzerland (Parenteral)
- 01 Jun 2014 Preclinical trials in Solid tumours in Switzerland (Parenteral) (Mundipharma EDO's pipeline)